Log in

OTCMKTS:SCIE - SpectraScience Stock Price, Forecast & News

0.00 (0.00 %)
(As of 01/26/2020 04:00 PM ET)
Today's Range
Now: $0.00
50-Day Range N/A
52-Week Range
Now: $0.00
Volume2.50 million shs
Average Volume546,055 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:SCIE



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive SCIE News and Ratings via Email

Sign-up to receive the latest news and ratings for SCIE and its competitors with MarketBeat's FREE daily newsletter.

SpectraScience (OTCMKTS:SCIE) Frequently Asked Questions

What is SpectraScience's stock symbol?

SpectraScience trades on the OTCMKTS under the ticker symbol "SCIE."

Has SpectraScience been receiving favorable news coverage?

News articles about SCIE stock have trended extremely negative on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SpectraScience earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for SpectraScience.

Who are some of SpectraScience's key competitors?

What other stocks do shareholders of SpectraScience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SpectraScience investors own include Agile Therapeutics (AGRX), Frequency Therapeutics (FREQ), Spectrum Brands (SPB), CytoDyn (CYDY), Dermira (DERM), Foamix Pharmaceuticals (FOMX), Fulcrum Therapeutics (FULC), Provention Bio (PRVB), Soligenix (SNGX) and Trimble (TRMB).

Who are SpectraScience's key executives?

SpectraScience's management team includes the folowing people:
  • Mr. Michael P. Oliver, CEO, Pres, COO & Director (Age 71)
  • Mr. Lowell W. Giffhorn, CFO & Sec. (Age 72)

How do I buy shares of SpectraScience?

Shares of SCIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SpectraScience's stock price today?

One share of SCIE stock can currently be purchased for approximately $0.00.

What is SpectraScience's official website?

The official website for SpectraScience is http://www.spectrascience.com/.

How can I contact SpectraScience?

SpectraScience's mailing address is 11568 SORRENTO VALLEY ROAD SUITE 11, SAN DIEGO CA, 92121. The company can be reached via phone at 858-847-0200.

MarketBeat Community Rating for SpectraScience (OTCMKTS SCIE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about SpectraScience and other stocks. Vote "Outperform" if you believe SCIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel